Table 3 Evaluation of drug efficacy using the ERS2 in a synechia patient
ERS2 | Patient-derived EoC | ||||||
|---|---|---|---|---|---|---|---|
Main-Criteria | Sub-Criteria | Full Points | Normal | Synechia | |||
Non-treated | +CXCL12 | +hCG | +VitD3 | ||||
Endometrial Receptivity | Intensity of Integrin αvβ3 | 5 | 4 | 1 | 3 | 5 | 3 |
Intensity of Osteopontin | 5 | 4 | 2 | 3 | 3 | 4 | |
Blood vessel formation | Area of angiogenic sprout | 5 | 3 | 1 | 5 | 1 | 4 |
Area of blood vessel | 5 | 4 | 1 | 5 | 3 | 4 | |
Total | 20 | 15 | 5 | 16 | 12 | 15 | |
ERS2 | Â | Receptive | Non-Receptive | Receptive | Receptive | Receptive | |
IVF-ET outcome prediction | Â | Success | Fail | Success | Success | Success | |
Clinical pregnancy outcome | Â | Success | N/A (On-hold with issues of collecting good embryos) | N/A | N/A | N/A | |
